-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$8.75573.08% Upside
AN2 Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover AN2 Therapeutics, Inc.?
AN2 Therapeutics, Inc. has been rated by research analysts at Leerink Partners, Evercore ISI, JMP Securities, Oppenheimer in the past 90 days.